Compare Kohl's Corporation (KSS) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kohl's Corporation vs ResMed Inc. — how do they compare? Kohl's Corporation trades at $17.36 (market cap $1.99B), while ResMed Inc. trades at $196.66 (market cap $28.81B). The key difference: ResMed Inc. is far larger — about 14.5× Kohl's Corporation's market cap, and Kohl's Corporation pays the higher dividend (2.85%). Which is the better fit depends on your goals.
| KSS | RMD | |
|---|---|---|
Market Cap | $1.99B | $28.81B |
Sector | Consumer Cyclical | Health |
52-Week High | $24.71 | $293.73 |
52-Week Low | $10.42 | $182.82 |
Enterprise Value | $8.10B | $27.99B |
Dividend Yield | 2.85% | 1.21% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kohl's (KSS) trades at $17.59, up 1.68% on the day, with a bullish technical signal from moving averages. The stock shows deep value metrics with a P/E of 7.27 and P/B of 0.49, while recent earnings beats and a 10% jump in juniors sales (Zacks, 2026-06-30) signal operational improvements. Cash flow turned positive in 2026 projections at $276M, and the company is focusing on proprietary brands and value initiatives to drive traffic.
Outlook: Turnaround efforts under CEO Michael Bender show early progress, but revenue declines persist. Investment case hinges on margin expansion and market share recovery. Risks include intense retail competition and macroeconomic pressure on consumer spending. Analyst consensus is mixed with a $16.75 price target below current levels, suggesting cautious optimism amid execution uncertainty.
ResMed (RMD) trades at $198.61, down 0.19% on the day, with a neutral technical signal and bearish moving averages. The company shows strong fundamentals, with Q1 2026 EPS beating estimates at $2.86 and revenue growth from $5.15B in 2025 to a projected $5.5B in 2026. Recent news highlights the sale of its MatrixCare business for $490 million, sharpening focus on core sleep and respiratory care markets. Analyst consensus is a Buy with a $245.88 price target, implying significant upside.
The outlook for RMD is positive, driven by consistent earnings beats, robust cash flow growth, and strategic divestitures. Key opportunities include market leadership in sleep apnea and digital health innovation. Risks involve competitive pressures from GLP-1 drugs and macroeconomic headwinds. Institutional sentiment is mixed but leans bullish on long-term growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Kohl's Corporation
Kohl's operates 1,165 department stores in 49 states that sell moderately priced private-label and national brand clothing, shoes, accessories, cosmetics, and home furnishings. Most of these stores are in strip centers. Kohl's also operates a large digital sales business. Women's apparel is Kohl's largest category, having generated 27% of its 2021 sales. The retailer, headquartered in Menomonee Falls, Wisconsin, opened its first department store in 1962.
Read more on KSS →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
